GSE216043 cisplatin 11 v 4 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE216043_cisplatin_11_v_4_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE216043_cisplatin_11_v_4_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE216043_cisplatin_11_v_4_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE216043_cisplatin_11_v_4_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

Rho GTPase activating protein 23

Gene

cytochrome P450 family 2 subfamily B member 7, pseudogene

Gene

A-kinase anchoring protein 17A

Gene

MT-CO2 pseudogene 12

Gene

metastasis associated lung adenocarcinoma transcript 1

Gene

TP53 target 1

Gene

MT-ATP6 pseudogene 1

Gene

long intergenic non-protein coding RNA 1128

Gene

HERC2 pseudogene 9

Gene

long intergenic non-protein coding RNA 632

  • Gene

    Rho GTPase activating protein 23


  • Gene

    cytochrome P450 family 2 subfamily B member 7, pseudogene


  • Gene

    A-kinase anchoring protein 17A


  • Gene

    MT-CO2 pseudogene 12


  • Gene

    metastasis associated lung adenocarcinoma transcript 1



  • Gene

    MT-ATP6 pseudogene 1


  • Gene

    long intergenic non-protein coding RNA 1128


  • Gene

    HERC2 pseudogene 9


  • Gene

    long intergenic non-protein coding RNA 632

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.